Seven-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3 vs. 6 months) for patients with high-risk stage II colon cancer: ...
This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
Subgroup analyses are an important part of the analysis of a comparative clinical trial. However, they are commonly overinterpreted 1 – 4 and can lead to further research that is misguided or, worse, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results